Haematology is a complex and challenging area of medicine and we are doing everything we can to find innovative solutions for those affected by diseases of the blood
Haemophilia is an inherited single gene disorder with an incidence of 1 per 10,000 births; affecting men (women are only carriers) in which the blood doesn’t clot normally. With more than two lakh cases, India is home to the second largest population of People with Haemophilia.
For more than 20 years, Roche has been innovating and delivering medicines for people with diseases of the blood. With the rise of novel therapies within haemophilia, we are working closely with all corners of the global haemophilia community – through our efforts to help improve the provision of treatments for those who need it most; through our dedication towards supporting patients at all stages of their haemophilia journey; and ultimately helping to transform the way haemophilia is treated and managed.
Hemlibra (Emicizumab), a prophylactic treatment for People with Haemophilia A (PwHA), is the first subcutaneous injection that can be self administered with flexible dosing options, where the maintenance dose can be selected based on physician and patient/caregiver dosing regimen preference. It is a standard of care for Haemophilia A patients, and prevents bleeding disorders due to restored clotting ability in people. It is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in all age groups including newborn and older, with haemophilia A.
Defining the severity of Haemophilia A?
- Occurs when someone has between 5-40% of the normal amount of clotting factor.6
- Usually becomes apparent after a wound or medical procedure.7
- Women may also have problems controlling bleeding associated with menstruation or childbirth.7
- Occurs when someone has between 1-5% of the normal amount of clotting factor.6
Symptoms are similar to mild haemophilia A, but can also cause:8
- Bleeding into muscles and joints, which if not treated can lead to long-term pain, swelling and stiffness.
- Occurs when someone has less than 1% of the normal amount of clotting factor.6
- Potentially life-threatening and joint bleeding is more frequent and severe.8
- People with severe haemophilia A also experience spontaneous bleeding.8
1. Flood E, et al. Illustrating the impact of mild/moderate and severe haemophilia on health-related quality of life: hypothesised conceptual models. European Journal of Haematology 2014; 93: Suppl. 75, 9–18.
2. Srivastava, A, Santagostino, E, Dougall, A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020: 26 (Suppl 6): 1-158.
3. Iorio A et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. Ann Intern Med 2019 Oct 15;171(8):540-546.
4. https://elearning.wfh.org/elearning-centres/introduction-to-hemophilia/#symptoms_and_diagnosis_hemophilia. Accessed on 10.03.2022.
5. World Federation of Hemophilia. Report on the annual global survey 2020. [Internet; cited 2022 February] Available from: http://www1.wfh.org/publications/files/pdf-2045.pdf
6. White GC, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis
and Haemostasis. Thromb Haemost. 2001 Mar;85(3):560.
7. Haemophilia Foundation Australia. Living with mild haemophilia. [Internet; cited 2022 February] Available from: https://www.haemophilia.org.au/HFA/media/Documents/Haemophilia/Mild%20haemophilia/
8. NHS. Symptoms of haemophilia [Internet; cited 2022 February]. Available from: https://www.nhs.uk/conditions/haemophilia/symptoms/.